Efficacy and Safety of DEB-BACE Combined With PD-1 Inhibitors in Stage II/III NSCLC With Standard Treatment Failure

Exclusion Criteria

• •The patient has previously received interventional therapy \[iodine seed implantation, ablation, bronchial arterial chemoembolization (BACE) therapy\], or received immunotherapy during the first-line standard treatment.
• •The patient is accompanied by other malignant tumors and had not been cured.
• •White blood cell \< 3×10\*9/L, absolute value of neutrophils \< 1.5×10\*9/L, neutrophil/lymphocyte ratio ≥ 3, platelet count \< 50×10\*9/L, hemoglobin concentration \< 90 g/L.
• •Liver and kidney dysfunction (creatinine \> 176.8 μmol/L; aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) \> 2 times the upper limit of normal).
• •Uncorrectable coagulopathy or active hemoptysis.
• •Patient with active infections requires antibiotic treatment.
• •Patient has uncontrollable hypertension, diabetes, and cardiovascular disease with obvious symptoms.
• •Allergy to contrast agents.
• •Women with pregnancy or lactation.